|Chemical and physical data|
|Molar mass||375.468 g·mol−1|
|3D model (JSmol)|
4'-Hydroxynorendoxifen is a synthetic, nonsteroidal antiestrogen of the triphenylethylene group. It is a dual selective estrogen receptor modulator (SERM) and aromatase inhibitor (AI), and was derived from tamoxifen, a SERM, and norendoxifen, a metabolite of tamoxifen that has been found to act as an AI. The drug has been suggested for potential development as a treatment for estrogen receptor (ER)-positive breast cancer. It was synthesized in 2015.
- Lv, Wei; Liu, Jinzhong; Skaar, Todd C.; Flockhart, David A.; Cushman, Mark (2015). "Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities". J. Med. Chem. 58 (6): 2623–48. doi:10.1021/jm501218e. PMC 4687028. PMID 25751283.
- Nagini, Siddavaram (2017). "Breast cancer: Current molecular therapeutic targets and new players". Anti-Cancer Agents in Medicinal Chemistry. 17 (2): 152–163. doi:10.2174/1871520616666160502122724. PMID 27137076.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|